In 2022: Cancer remains the second leading cause of death in Germany.

TORebovites were also the second leading cause of death in Germany in 2022. As the Federal Statistical Office announced on Friday to mark World Cancer Day this Sunday, 231,533 people died from the disease last year. This was a good 20,000 more patients than 20 years ago. However, the proportion of cancer deaths overall fell from 25 percent to 21.7 percent over the same period. According to statisticians, the increase in the number of people dying from cancer is due, among other things, to the increase and aging of the population.

Thanks to improvements in prevention, screening and treatment, the number of inpatient cancer cases has decreased from 1.56 million in 2002 to 1.4 million patients in 2022. This is the lowest level in 20 years. The most common cause of death (358,200 people) was diseases of the circulatory system. They were also the reason for the majority of inpatient visits (15 percent), ahead of injuries, poisoning and other consequences of external causes and diseases of the digestive system (about ten percent). Eight percent of all inpatient visits were related to cancer.

Almost a fifth of all cancer-related deaths were caused by lung and bronchus cancer (45,200), followed by colon cancer (24,300), pancreatic cancer (19,200), breast cancer (19,100) and prostate cancer (15,600). A good 54 percent of those who died from cancer were men and 46 percent were women. People aged 60 to 79 years are especially likely to be treated in hospital for cancer (54 percent). A fifth (20 percent) were aged 40 to 59 years, and a further 20 percent were aged 80 years or older.

On the other hand, young people are rarely treated for cancer: only five percent of cancer patients were under 40 years of age. Cancer was the most common cause of death for people aged 40 to 74, with more than one-third of deaths (35 percent) in this age group being the result of cancer.

Source: Frantfurter Allgemeine

Get in Touch

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Latest Posts